MedPath

Comparison of Dentin Hypersensitivity Reduction Over a 1-month Period

Not Applicable
Completed
Conditions
Dentin Sensitivity
Registration Number
NCT04351412
Lead Sponsor
King Abdulaziz University
Brief Summary

Here we assessed the clinical effectiveness of Gluma, fluoride varnish, and the Tetric N-Bond one-step self-etch system in alleviating DH instantly and over 1 month, after a single topical application.A randomized, double-blind, clinical trial was conducted on 55 patients (25 males, 30 females; age: 20-49 years). Seventy teeth were randomly assigned to three groups: Gluma (n = 24); fluoride varnish (n = 23); and Tetric N-Bond adhesive (n = 23). Sensitivity to tactile, air blast, and cold stimuli were investigated.. A visual analogue scale was used to assess tactile stimuli, and the Schiff Cold Scale to assess air blast and cold stimuli. DH was evaluated immediately post-treatment, and at the 2-week and 1-month follow-up. Between-group and within-group comparisons were made.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
55
Inclusion Criteria
  • Middle-aged adult population who usually complains of Dentin Hypersensitivity.
  • Age range 20-49 years, that visit the dental hospital at King Abdul-Aziz university (KAUDH) who would have at least one or two teeth with DH
  • Those with recession of the gingiva, teeth erosion or abrasion.
  • Patients agreed to participate in the study.
Exclusion Criteria
  • Patients going through professional desensitizing treatment during the previous three months; Using desensitizing tooth paste in the last two months
  • Chronic; far on progress periodontal disease; treatment for periodontal disease;
  • Teeth with ICDAS (International Caries Detection and Assessment System) score 4
  • Teeth diagnosed for irreversible pulpitis; root canal treated teeth
  • Teeth covered with crowns; bridge
  • Teeth with cervical restorations interfering with the evaluation
  • Medically compromised patients currently using medications like anticonvulsants, antihistamines, antidepressants, sedatives or daily analgesics.
  • Pregnant or lactating women; were also excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Assess dentine hypersensitivity score to stimuli immediately after treatment by interventionFrom baseline to immediately after treatment with intervention

Scores of DH for tactile stimulus were recorded using visual analogue scale and for cold, and air blast stimuli using the Schiff Cold Air Sensitivity Scale 18 were recorded immediately after treatment with intervention and compared score to baseline.

Assess dentine hypersensitivity score to stimuli at BaselineBaseline before treatment

Scores of DH for tactile stimulus were recorded using visual analogue scale and for cold, and air blast stimuli using the Schiff Cold Air Sensitivity Scale 18 at baseline.

Assess dentine hypersensitivity to stimuli at two-weeks follow up after treatment by interventionFrom baseline to two-weeks follow up after treatment with intervention

Scores of DH for tactile stimulus were recorded using visual analogue scale and for cold, and air blast stimuli using the Schiff Cold Air Sensitivity Scale 18 were recorded at two-weeks follow up after treatment with intervention and compared score to baseline and immediate treatment scores.

Assess dentine hypersensitivity to stimuli at one month follow up after treatment by interventionFrom baseline to one month follow up after treatment with intervention

Scores of DH for tactile stimulus were recorded using visual analogue scale and for cold, and air blast stimuli using the Schiff Cold Air Sensitivity Scale 18 were recorded at one month (30 days) follow up after treatment with intervention and compared score to baseline and immediate treatment, and two weeks follow up visit scores.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

King Abdulaziz University

🇸🇦

Jeddah, Saudi Arabia

King Abdulaziz University
🇸🇦Jeddah, Saudi Arabia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.